C0527090|gadoxetic acid disodium|
CL319935|Laxative Preparation|
CL343378|childhood intracranial mixed germ cell brain tumor|
CL347233|Hemoperitoneum|
CL383525|Physician Data Query, 2008_06|
CL384561|Xp22.32|
CL386200|Abnormal_Cell_Kind|
CL386201|Activity_Kind|
CL386207|Biological_Process_Kind|
CL386226|Chemicals_and_Drugs_Kind|
CL386227|Chemotherapy_Regimen_Kind|
CL386257|Diagnostic_and_Prognostic_Factors_Kind|
CL386266|EO_Anatomy_Kind|
CL386267|EO_Findings_and_Disorders_Kind|
CL386271|Findings_and_Disorders_Kind|
CL386277|Gene_Kind|
CL386278|Gene_Product_Kind|
CL386356|Organism_Kind|
CL386369|Properties_or_Attributes_Kind|
CL386439|Anatomy_Kind|
CL386490|Equipment_Kind|
CL386536|Molar Mass|
CL386537|Molecular_Abnormality_Kind|
CL386541|NCI_Kind|
CL386549|Pathway_Kind|
CL387549|Gastrointestinal Anastomotic Leakage|
CL387626|MYCN Messenger RNA Expression|
CL387639|Ribonucleotide Reductase Messenger RNA Expression|
CL387654|Based on BioCarta online maps of molecular relationships, adapted for NCI use., 0812D|
CL387655|U.S. Centers for Disease Control and Prevention, 0812D|
CL387656|Clinical Data Interchange Standards Consortium, 0812D|
CL387657|City of Hope, 0812D|
CL387658|Cancer Research Center of Hawaii, 0812D|
CL387659|Common Terminology Criteria for Adverse Events, 0812D|
CL387660|DICOM, 0812D|
CL387661|Division of Cancer Prevention Program, 0812D|
CL387662|NCI Developmental Therapeutics Program, 0812D|
CL387663|Food and Drug Administration, 0812D|
CL387664|Health Level 7, 0812D|
CL387665|International Conference on Harmonization, 0812D|
CL387666|NCI Mouse Terminology, 0812D|
CL387667|KEGG Pathway Database, 0812D|
CL387668|National Cancer Institute Thesaurus, 2008_12D|
CL387669|NCI-GLOSS (Cancer.gov Dictionary), 0812D|
CL387670|Registry Nomenclature Information System, 0812D|
CL387671|Unified Code for Units of Measure, 0812D|
CL387712|Excision Repair Cross-Complementing 1 Messenger RNA Expression|
